The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution™ system to isolate and concentrate a patient's own stem cells in approximately a one-hour period of time. This system will dramatically improve the speed in which personalized, cell-based therapies can be delivered to patients.

Cytori's MacroPore Biosurgery division develops and manufactures innovative bioresorbable, surgical implants. MacroPore Biosurgery manufactures the HYDROSORB™ family of FDA-cleared bioresorbable spine and orthopedic implants, which are distributed worldwide exclusively through Medtronic, Inc. Additionally, MacroPore Biosurgery is developing Thin Film bioresorbable implants exclusively for Senko Medical Trading Co., which has distribution rights exclusively in Japan.